Hey yo!!!!!!!! And you forgot the most important. Massive, massive debt and dullution!!!! And some paid advertising to boot.
PXYN.053-Praxsyn-Pharmaceuticals'-RISE-to-NET-PROFITS-Incredible-Reverse-Merger-Story
About once every year, a tiny company will go public, and have an amazing growth in revenues and profits, and the stock price will go up 1000% or more, and people will say.... if only I had known then what I know now.
In my opinion, Praxsyn Pharmaceuticals is that company for 2014-2015. At only .053 per share the stock has not yet shown the appreciation that the turnaround in it's financials since going public have warranted, but it should began to rise now, and continue throughout 2015, and here's why...
First, a little background on Praxsyn Pharmaceuticals
PXYN is a REVERSE MERGER company that just went public this year. Pharmacy Development Company (PDC) and Mesa Pharmacy, used the old PAWS shell to accomplish this going public, and in order to comply with SEC rules and FINRA rules, it took over 8 months for the company to accomplish updated 10K annual reports and accomplish the name change and updated symbol change to Praxsyn Pharmaceuticals PXYN.
Also with the old shell came some convertible debt and the PDC company also had some debts and it appears that some of those debts were exchanged for shares, and many of those were diluted into the markets over the summer and drove the stock price down from the .20 area to the .03 area in early fall. However, that selling appears to be done and the stock now has recently traded as high as .08 but fell back on the "sell on the news" reaction that many microcap stock have, as momentum traders leave a stock after anticipated NEWS or Earnings is posted. So that leaves us now with a NET PROFITABLE company as reported in the third quarter, with the prospects for much larger revenues and NET PROFITS in the fourth quarter, and then huge growth, and I am not hyping, HUGE GROWTH in 2015 in both Revenues and NET PROFITS.
There is a huge wealth of information in the 2014 SEC 10Q - 3rd quarter earnings report about what Praxsyn is doing, and I encourage all investors and potential investors to take about 30 minutes
